Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Increases By 28.3%

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 1,056,017 shares, an increase of 28.3% from the December 15th total of 822,858 shares. Currently, 19.9% of the company’s stock are short sold. Based on an average trading volume of 339,735 shares, the days-to-cover ratio is currently 3.1 days. Based on an average trading volume of 339,735 shares, the days-to-cover ratio is currently 3.1 days. Currently, 19.9% of the company’s stock are short sold.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock traded up $0.93 during mid-day trading on Monday, hitting $70.00. 301,279 shares of the stock were exchanged, compared to its average volume of 302,401. Monopar Therapeutics has a 12 month low of $26.06 and a 12 month high of $105.00. The company has a 50-day simple moving average of $74.36 and a 200 day simple moving average of $63.87. The company has a market capitalization of $467.60 million, a P/E ratio of -20.35 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Analysts predict that Monopar Therapeutics will post -1.65 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. BTIG Research reiterated a “buy” rating and set a $104.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, January 14th. Lake Street Capital initiated coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 price target on the stock. Leerink Partners started coverage on Monopar Therapeutics in a report on Monday, November 10th. They set an “outperform” rating and a $115.00 price objective for the company. Morgan Stanley initiated coverage on Monopar Therapeutics in a research note on Friday, January 9th. They issued an “overweight” rating and a $115.00 price objective for the company. Finally, Oppenheimer set a $115.00 target price on Monopar Therapeutics and gave the company an “outperform” rating in a research report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $107.00.

Insider Buying and Selling at Monopar Therapeutics

In other news, CFO Quan Anh Vu bought 1,500 shares of the stock in a transaction dated Friday, December 26th. The shares were bought at an average cost of $69.95 per share, with a total value of $104,925.00. Following the completion of the transaction, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at $104,925. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 20.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. purchased a new position in Monopar Therapeutics in the third quarter valued at about $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Monopar Therapeutics in the 2nd quarter worth approximately $34,000. BNP Paribas Financial Markets raised its holdings in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the period. AlphaQuest LLC lifted its stake in Monopar Therapeutics by 46.8% in the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock valued at $64,000 after purchasing an additional 569 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the period. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.